N/A N=24 The Effects of Respiratory Training on Voice
Muscle Tension Dysphonia
Primary: Post Training Lung Volume Initiation — 21.07; 27.04 % vital capacity relative to rest level — p=<0.0005
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=20 rTMS in Spasmodic Dysphonia
Spasmodic Dysphonia · Laryngeal Dystonia
Primary: Adverse Response to rTMS — 0; 0 Participants
N/A N=42 Laryngeal Vibration for Spasmodic Dysphonia
Spasmodic Dysphonia
Primary: Voice Assessment During First Visit — 0.045; 0.17; 0.13; -0.47 decibel
N/A N=30 Evaluating the Feasibility of Acapella® Choice as a Dysphonia Treatment
Muscle Tension Dysphonia · Vocal Fold Palsy · Vocal Cord Paralysis
Primary: Change in Baseline Cepstral/Spectral Index of Dysphonia (CSID) — 1.22; 4.45; 4.56; 3.13 score on a scale
N/A N=20 Respiratory Muscle Strength Training in Presbyphonia
Presbylarynx
Primary: Post-Treatment Mean in Voice Handicap Index Score — 15.00; 15.75; 18.50 score on a scale — p=0.041
N/A N=6 Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial
Spasmodic Dysphonia · Laryngeal Dystonia · Deep Brain Stimulation
Primary: Unified Spasmodic Dysphonia Rating Scale (USDRS) — 2.5; 3.75 units on a scale — p=0.025
Phase 3 N=32 Spasmodic Dysphonia Pain
Spasmodic Dysphonia
Primary: Pain Experienced — 2; 2; 2 score on a scale
N/A N=50 Transmembrane Electromyography (TM-EMG) for the Assessment of Neuromuscular Function in the Oropharynx
Obstructive Sleep Apnea · Amyotrophic Lateral Sclerosis · Muscular Dystrophies
Primary: Proof of Diagnostic Consistency — 95.7; 78.1; 90 % agreement
Phase 2 N=53 Voice Tremor in Spasmodic Dysphonia: Central Mechanisms and Treatment Response
Spasmodic Dysphonia · Voice Tremor
Primary: Number of Participants Who Reported Positive Effects. — 17; 20 Participants
N/A N=24 Motor Cortex as a Research & Therapeutic Target in TMD
Temporomandibular Joint Disorders
Primary: Number of Participants With Pain Relief as Measured by Visual Analog Scale (VAS) Decrease of 50% or Greater From Baseline — 4; 9 participants
N/A N=5 Dystonia Treatment With Injections Supplemented By Transcranial Magnetic Stimulation
Cervical Dystonia
Primary: Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 17; 16.6; 17; 15.8 score on a scale — p=0.691
N/A N=74 The Effectiveness of a Physiotherapy Technique in Patients With Chronic Myofascial Temporomandibular Disorder
Myofascial Pain Syndrome · Temporomandibular Disorder
Primary: Changes of Perceived Pain Between Three Time Points (Baseline, Post-treatment, and 3 Months Later) and Between Groups (Sham Simulation and Pressure Release Technique)…
Phase 2 N=22 DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Adductor Spasmodic Dysphonia · Voice Disorders · Spasmodic Dysphonia
Primary: Our Primary Outcome is the Difference in VHI-10 Score at 30 Days After Injection With DAXI. — 17.81 units on a scale — p=<0.001
N/A N=9 rTMS and Botulinum Toxin in Primary Cervical Dystonia
Primary Cervical Dystonia · Dystonia
Primary: Dystonia Severity as Assessed by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) — 13; 17 scores on a scale
N/A N=191 Managing Temporomandibular Disorder (TMD) Symptoms
Temporomandibular Joint Disorders
Primary: Characteristic Pain Intensity (Characteristic Intensity of Facial Pain) — 3.1; 2.9; 3.6 units on a scale — p=0.19
Phase 2 N=9 rTMS and Retraining in Focal Hand Dystonia
Focal Dystonia
Primary: Change From Baseline in Global Rating of Change at Posttest (Day 5) — 1.3; 1.2 units on a scale
Phase 4 N=16 Quantifying Musical Performance After Treatment With Myobloc in Musician's Dystonia
Focal Dystonia
Primary: Note Errors (Related to Errors in Duration) — 8.20; 5.79 msec — p==0.06
N/A N=13 Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
Spasmodic Dysphonia · Adductor Spasmodic Dysphonia · Voice Disorders
Primary: Laryngeal Adductor Reflex — 13 Participants
N/A N=16 Eustachian Tube Dysfunction Assessment
Eustachian Tube Dysfunction
Primary: Latency Between mLVP and mTVP Signals — 127.26 Time in milliseconds
N/A N=42 Quantifying Myofascial Dysfunction in Post-Stroke Pain
Myofascial Dysfunction
Primary: T1 Rho MRI Relaxation Time of Shoulder External Rotator (Milliseconds) — 29.09; 27.15 milliseconds
N/A N=80 Conservative Treatment of Patients With Temporomandibular Disorders
Temporomandibular Disorders
Primary: Patient-Rated TMD Pain, an 11 Point Numerical Rating Scale (NRS) — 0.9; 1.4; 1.6; 0.7 units on a scale
N/A N=12 Repetitive Transcranial Magnetic Stimulation (rTMS) for Dystonia and Tremor
Dystonia · Tremor
Primary: Cognitive Assessment Using MoCA Version 7.1 Scores — 25.45; 27 units on a scale
N/A N=146 Expiratory Muscle Training in Stroke
Stroke · Mastication Disorder · Temporomandibular Disorders
Primary: Change in Masticatory Performance — 24; 13; 25; 16 percentage of masticated peanuts
N/A N=28 Immediate Effect of Ultrasound Therapy on Bilateral Masseter Myalgia: Randomized Single Blinded Investigational Trial
Temporomandibular Joint Dysfunction Syndrome
Primary: Self Report of Pain — -.86; -2.0; -1.4; -1.3 Scores on pain intensity scale — p=0.17
N/A N=30 MyoVoice to Restore Natural, Hands-free Communication to Individuals With Vocal Impairments
Rehabilitation of Speech and Language Disorders · Speech Disorders · Speech, Alaryngeal
Primary: Pitch Recognition Accuracy — 7.70 Percent agreement to reference pitch
N/A N=38 Efficacy of Capacitive-Resistive Therapy on the Treatment of Myofascial Pain
Myofascial Pain Syndrome of Neck
Primary: Visual Analog Scale (VAS) Score Change — 5.9; 5.1; 4.1; 2.3 score on a scale
N/A N=24 Duloxetine for Treatment of Painful Temporomandibular Joint Disorder
Temporomandibular Joint Disorders
Primary: Spontaneous Pain as Measured by Visual Analog Scale at Baseline and at End of 6 Weeks. — 42.9; 51.4; 30.4; 44 units on a scale
Phase 3 N=108 Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
Spasmodic Dysphonia · Voice Tremor
Primary: Symptom Severity — 28.0; 18.6; 14.2; 12.3 score on a scale — p=0.01
Phase 2 N=79 Traditional Chinese Medicine (TCM) for Temporomandibular Dysfunction (TMD): A Whole Systems Multi-site Trial
Temporomandibular Dysfunction
Primary: Characteristic Facial Pain Score — 6.52; 6.55; 5.11; 5.47 units on a scale — p=0.020
N/A N=8 Essential Voice Tremor: A Study of Botulinum Toxin Treatment and Injection Augmentation
Essential Tremor
Primary: Vocal Tremor Scoring System (VTSS) — 0.57; 0.57; 1; 0.43 units on a scale